Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110900 · ClinicalTrials.gov registry record · Phase 4
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
A Phase 4 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03110900: Clinical Trial Phase 4 study, sponsored by University of Arkansas.
NCT03110900 is a Phase 4 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03110900, a Phase 4 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
Primary Outcome
Change in agitation level on the PANSS from baseline up to 120 minutes -- terminated by sponsor before results available
Interventions
- DRUG Haloperidol + lorazepam
- DRUG Loxapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-09-30 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 4 |
Why NCT03110900 stopped before completion
NCT03110900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Haloperidol + lorazepam is the first listed.
NCT03110900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03110900 about?
NCT03110900 is a clinical study titled "Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation". The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
What is the current status of trial NCT03110900?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-09-30. Estimated completion is 2018-04-04.
What interventions are being tested in trial NCT03110900?
The interventions under investigation include: Haloperidol + lorazepam (DRUG), Loxapine (DRUG).
Who is sponsoring clinical trial NCT03110900?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03110900's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI